Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review

Arthritis Care Res (Hoboken). 2011 Jan;63(1):65-78. doi: 10.1002/acr.20338.

Authors

Gabrielle van der Velde¹, Ba' Pham, Márcio Machado, Luciano Ieraci, William Witteman, Claire Bombardier, Murray Krahn

Affiliation

¹ Toronto Health Economics and Technology Assessment Collaborative and Institute for Work and Health, Toronto, Ontario, Canada. gabrielle.vandervelde@theta.utoronto.ca

PMID: 20740606
DOI: 10.1002/acr.20338

No abstract available

Publication types

Comparative Study
Review
Systematic Review

MeSH terms

Animals
Antirheumatic Agents / economics*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / economics*
Cost-Benefit Analysis / economics
Cost-Benefit Analysis / trends
Humans
Immunologic Factors / economics*
Immunologic Factors / therapeutic use*

Substances

Antirheumatic Agents
Immunologic Factors